Under construction – not a live service
Sign in
Taking peoplePhase 1

Tests EXS73565 taken by mouth in adults with returning or resistant B-cell cancers

Tests EXS73565 taken by mouth in adults whose B-cell cancers returned or resisted treatment.

Key facts

Who runs it
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Where
Bordeaux, Marseille, and Nantes, FranceSee the 3 sitesAlso in 8 other countries, 19 sites
Registry title
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
85 people, planned
Started
31 Mar 2025
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • EXS73565
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose B-cell blood cancer has come back or has not responded to standard treatment. Everyone takes the study drug EXS73565 by mouth.

Age
18 years or older
Sex
Men and women can join
Disease stage
Cancer of the B-cells that came back after standard care, got worse during standard care, or cannot be treated with standard care. Types: CLL (including Richter's transformation), mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or Waldenström macroglobulinaemia. ECOG performance status 0-1.
Earlier treatment
Must have relapsed after standard of care, progressed during it, or not be suited to it. No anticancer treatment within 14 days or 5 half-lives (whichever is shorter) before the first dose, except palliative radiotherapy.

Main reasons for not taking part

  • Known cancer in the central nervous system or primary CNS lymphoma
  • Another active or earlier cancer within 5 years (prior cancers only with documented Sponsor approval)
  • Any medical or psychiatric condition that could put safety at risk or prevent taking part
  • Anticancer or investigational treatment within 14 days or 5 half-lives before the first dose

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age ≥18 years at the time of signing the informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia
  • Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy

Who cannot take part

  • Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment
  • Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study
  • Known central nervous system (CNS) malignancy or primary CNS lymphoma
  • Concurrent active or previous malignancy (other than the primary lymphoma/CLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval

Where in France

Also in 8 other countries, 19 sites

  • Institut BergonieBordeaux, FranceNot yet recruiting
  • Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
  • Centre Hospitalier Universitaire de NantesNantes, FranceNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

The group in the trial

  • EXS73565Treatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies
Plain-language title
Tests EXS73565 taken by mouth in adults with returning or resistant B-cell cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 August 2026